COLUMBIA, Md. – The U.S. Food and Drug Administration has given digital health company WellDoc clearance for a non-prescription version of its BlueStar mobile healthcare app for people with Type 2 diabetes. “We can now integrate BlueStar more seamlessly into the health care ecosystem as we commercialize the product and significantly scale it by working with our existing partners, as well as others with which we are actively engaged,” said Kevin McRaith, WellDoc president and CEO, in a statement. Based on the FDA clearance, WellDoc will offer BlueStar and BlueStar Rx. The non-prescription version will have all of the same features as the prescription version, except for an insulin calculator.
You are here: / / BlueStar receives FDA clearance for diabetes management